|
... certain stocks on your trading list. We have been all over the trends of late, calling them perfectly I am proud to say. For example, Plandai (OTCQB – PLPL)) might be the best performer of the year, ...
With the announcement of its recent license agreement with Diego Pellicer, Inc. and Diego Pellicer Worldwide Inc., Plandaí Biotechnology, Inc. (OTCQB –PLPL - $0.49 – Spec Buy) has positioned itself at ...
... the Marijuana Wave
Throughout 2013, management and the scientific team at Plandaí Biotechnology, Inc. (OTCQB –PLPL - $0.40 – Spec Buy) succeeded in making meaningful progress on its flagship Phytofare™ ...
... (OTCQB – PLPL - $0.49 – Spec Buy) is an innovative development stage company making a foray into the green tea extracts market with its proprietary Phytofare™ Catechin Complex.
One of the many benefits ...
In a move that we believe will add meaningful value to the overall company, Plandaí¬ Biotechnology, Inc. (OTCQB – PLPL - $0.51 – Spec Buy) recently announced that it has formed a new wholly-owned subsidiary, ...
... year 2013, investors and management teams alike are turning toward 2014 and the grand prospects that lie ahead, and Plandaí Biotechnology, Inc. (OTCQB – PLPL - $0.51 – Spec Buy) is no exception. The ...
...
For more information, refer to our previous sponsored PLPL Reports, Updates and Hot Topics by visiting www.GoldmanResearch.com
NVLX
Senior Analyst: Robert Goldman
Rob Goldman has over ...
Less than a month removed from acquiring rights to a cutting edge nano and micro particle entrapment technology, Plandaí Biotechnology, Inc. (OTCQB – PLPL) has already secured a lucrative out-licensing ...
With October (The Breast Cancer Awareness Month) around the corner, it is interesting to note that Plandaí¬ Biotechnology, Inc.’s (OTCQB – PLPL - $0.55 – Spec Buy) Phytofare™ Citrus Products may prove ...
Plandaí Biotechnology, Inc. (OTCQB – PLPL - $0.48 – Spec Buy) has made significant strides in recent months as it nears an inflection point which will migrate the Company from the development phase to ...
Earlier this week, Plandaí Biotechnology, Inc. (OTCQB – PLPL - $0.50 – Spec Buy) recently released landmark news that after further review, paves the way for the formulation of ingredients with tremendous ...
... MICROCAP HOT TOPICS
August 30, 2013
Plandaí Biotechnology’s Phytofare™Citrus Products Aid Diabetics
Plandaí Biotechnology (OTCQB – PLPL - $0.67 – Spec Buy) is set to release ...
... – PLPL - $0.75 – Spec Buy). Plandaí plans to introduce highly bioavailable extract products under the Company’s Phytofare™ line that specifically contain these polyphenols which can be used ...
Shares of Plandaí Biotechnology Inc. (OTCQB – PLPL - $0.66 – Spec Buy) closed at a new 52-week high yesterday, despite the current stock market slump. The shares may be further bolstered by results of ...
... (OTCQB – PLPL - $0.58 – Spec Buy) malaria study, it nonetheless supports the Company’s series of tests to date that green tea extracts demonstrate an antimalarial effect.
In the Italy-based study, the ...
As we near the end of the dog days of August, the relatively sleepy and under-followed Plandaí¬ Biotechnology, Inc. (OTCQB – PLPL - $0.61 - Spec Buy) has matched its 52-week high this week and appears ...
... (OTC QB – PLPL - $0.54 – Spec Buy).
Investment and Company Research Opportunity Research MICROCAP HOT TOPICS
August 13, 2013
European Opportunity for Plandaí ...
Plandaí Biotechnology, Inc. (OTCQB – PLPL - $0.53 - Spec Buy), which is slated engage in a weight loss study to test the efficacy of its flagship product, is well-positioned to assist in the fight against ...
... Plandaí Biotechnology, Inc. (OTCQB – PLPL - $0.495 – Spec Buy) appears to have a leg up on the competition in a product category worth hundreds of millions in annual sales.
Later this year, Plandaí ...
Given the numerous upcoming corporate and developmental events, PLPL shareholders will be hugely rewarded as milestones are reached in 2H13.
Investment and Company Research ...
The poor side effect profile for an already approved malaria drug serves as a major boost to Plandai Biotechnology Inc.’s (OTCQB – PLPL - $0.47 - Spec Buy) new malaria treatment efforts.
Investment ...
...
Leveraging these and other studies, Plandaí Biotechnology Inc.’s (OTCQB – PLPL $0.48 – Spec Buy) advanced products from Green Tea Extracts can be used to target this ever-present and growing market. ...
... – PLPL - $0.465)
Price Target: $2.00
Rating: Speculative Buy
COMPANY SNAPSHOT
INVESTMENT HIGHLIGHTS
...
... the growth rate in the space remains high and Plandaí Biotechnology, Inc. (OTCQB – PLPL - $0.43 – Spec Buy) is primed to take advantage of the offering’s increased demand. In fact, today, EGCG is ...
... Inc. (OTCQB – PLPL - $0.47 – Spec Buy).
Investment and Company Research
Opportunity Research
MICROCAP HOT TOPICS
...
... – PLPL - $0.48 – Spec Buy) that demonstrated the greatest absorption of the key nutrients, known as catechins, found in green tea into the bloodstream, many of the studies conducted on green tea’s ...
Due to the high absorption rates in its flagship offerings, Plandaí Biotechnology Inc. (OTCQB – PLPL - $0.52 - Spec Buy) may soon enter the colon cancer fighting arena.
Investment and Company ...
... report that forecast the consumption of sports and nutrition foods and drinks to be a $55 billion market in the U.S. alone by 2018.
Plandaí Biotechnology Inc.’s (OTCQB – PLPL - $0.50 – Spec Buy) ...
... trouble than they bargained for. It is a good thing that Plandaí Biotechnology (OTCBB: PLPL), may offer products that can be adapted to treat various skin ailments and conditions caused by excessive ...
... may now be a thing of the past based on extremely positive test results generated by the flagship product designed by Plandai Biotechnology Inc. (OTCQB – PLPL $0.515 – Spec Buy). Plandai is ...
... is worth a pound of cure”, which may soon refer to Plandaí Biotechnology, Inc. (OTCQB - PLPL - $0.505 - Spec Buy). Plandaí develops highly bioavailable, phytonutrient extracts rich in anti-oxidant ...
... by Plandai Biotechnology, Inc. (OTCQB – PLPL) which has made great strides toward treating and preventing malaria.
Investment and Company Research Opportunity Research MICROCAP HOT TOPICS ...
... wellness, a boon for PLPL.
Investment and Company Research Opportunity Research MICROCAP HOT TOPICS
June 13, 2013
PLANDAÍ BIOTECHNOLOGY POSITIONS ITSELF IN WAR ...
... – PLPL - $0.54 – Spec Buy)
Investment and Company Research
Opportunity Research
HOT TOPICS
June 11, 2013
PLANDAI’S ...
... as a treatment for Alzheimer’s disease. Success in developing a treatment for or prevention of Alzheimer’s could have a very favorable impact on Plandai Biotechnology Inc. (OTCQB – PLPL - $0.53 ...
... such as Epigallocatechin gallate (EGCG), the flagship offering of Plandai Biotechnology Inc. (OTCQB - PLPL - $0.53 - Spec Buy) will soon be used to support weight management. The Company secured a distribution ...
... that the direct costs of treating malaria is $12 billion annually, the potentially low-cost and highly efficacious Plandai Biotechnology Inc. (OTCQB – PLPL - $0.51 – Spec Buy) treatment under development ...
... [email protected]
May 29, 2013
PLANDAI BIOTECHNOLOGY, INC. (OTC:QB - PLPL - $0.46)
Price Target: $2.00
Rating: Speculative Buy
...
Until the arrival of Plandai Biotechnology, Inc. (OTCQB – PLPL), even many wellness pundits were unaware that substantial increases in bioavailability and effectiveness of some products, like green tea ...
|
||
|
|
||